
Opinion|Videos|April 2, 2025
Collaborating for Better Atopic Dermatitis (AD) Care: How Primary Care and Dermatology Can Work Together
Author(s)Lisa Swanson, MD
A panelist discusses how effective coordination between primary care providers and dermatologists creates a complementary care model that optimizes atopic dermatitis management through shared decision-making, clear communication pathways, and defined roles for each specialty.
Advertisement
Collaborating for Better Atopic Dermatitis (AD) Care: How Primary Care and Dermatology Can Work Together
Roles and Responsibilities
- Primary Care Physicians (PCPs): Initial diagnosis, management of mild-to-moderate disease, coordination of care, holistic patient monitoring
- Dermatologists: Management of severe/recalcitrant cases, specialized testing, initiation of advanced therapies, procedural interventions
- Shared Responsibilities: Patient education, comorbidity identification, trigger avoidance strategies, treatment adherence support
Optimal Referral Pathway
- Referral Criteria:
- Diagnostic uncertainty
- Inadequate response to optimized first-line therapy (2-4 weeks)
- Severe/widespread disease affecting >10% BSA
- Significant psychosocial impact
- Recurrent secondary infections
- Consideration for systemic therapy
- Referral Communication: Include treatment history, response to therapies, comorbidities, current medications, impact on quality of life
Collaborative Care Models
- Shared Care Protocols: Define management algorithms with clear transitions of care
- Electronic Consultation: Virtual case reviews before formal referrals
- Integrated EMR Systems: Shared documentation of treatment plans and outcomes
- Co-management Arrangements: Alternating visits between specialties for complex cases
Knowledge Transfer Strategies
- Joint CME Programs: Cross-specialty education on AD management
- Practice-Based Learning Networks: Case-based discussions between PCPs and dermatologists
- Standardized Tools: Shared assessment metrics (EASI, POEM, DLQI) across settings
- Decision Support Systems: EMR-integrated guidelines for therapy selection
Improving Access to Dermatologic Care
- Teledermatology Options: Store-and-forward or live video consultation
- PCP Extension Programs: Dermatologist-supported management in primary care
- Nurse Practitioner/Physician Assistant Integration: Mid-level providers with specialized AD training
- Group Visits: Multidisciplinary education sessions for AD cohorts
Quality Improvement Initiatives
- Care Pathways: Standardized, evidence-based approaches across settings
- Regular Outcome Measurement: Tracking disease severity and quality of life metrics
- Patient Registries: Shared databases for monitoring complex patients
- Audit and Feedback: Regular review of referral appropriateness and outcomes
Addressing Common Challenges
- Communication Gaps: Structured referral forms with clear response expectations
- Resource Limitations: Prioritization strategies for dermatology access
- Insurance Barriers: Collaborative advocacy for coverage of needed therapies
- Geographical Disparities: Telehealth solutions for underserved areas
Future Directions
- Integrated AD Centers: Multidisciplinary clinics for complex cases
- Shared Decision-Making Tools: Patient-centered collaborative care planning
- Population Health Approaches: Risk stratification and proactive management
- Digital Health Platforms: Patient-reported outcomes shared between specialties
Advertisement
Related to this article

ObesityWeek 2026: Once-weekly semaglutide reduced BMI by 13.5% vs a 2.7% gain with placebo at 68 weeks in children 6 to <12 years with obesity.

The FDA approved at-home dexmedetomidine film for acute agitation in adults with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.

Ascletis submits an FDA IND for ASC30_39, an oral GLP-1–amylin obesity combination supported by preclinical data.

AHA 2026: Yoga-based cardiac rehabilitation improved quality of life and walking distance in patients with HFrEF but did not significantly reduce death, hospitalization, or stroke.

The ACS 2026 prostate cancer screening guidelines recommend risk-based PSA testing beginning at age 45 or 50, with updated follow-up thresholds.

Retatrutide trials report less knee osteoarthritis pain; ixekizumab plus tirzepatide shows exploratory ACR50 benefits in psoriatic arthritis.

Asundexian reduced relative ischemic stroke risk by 26% alongside antiplatelet therapy, with bleeding concerns in older adults.
Advertisement
Advertisement
Trending on Patient Care Online
1
Making Liver Fibrosis Testing Routine, With Zobair Younossi, MD, MPH
2
Sequential NITs Rule Out Advanced Fibrosis in Primary Care
3
Semaglutide Reduces BMI by 13.5% in Children Aged 6-11 in Step Young Trial
4
FDA Approves Dexmedetomidine as First At-Home Treatment for Acute Agitation
5

